# Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)

> **NCT00541229** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 103 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** sitagliptin phosphate
- **DRUG:** sitagliptin phosphate
- **DRUG:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT00541229
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08-24
- **Primary completion:** 2008-06-17
- **Final completion:** 2008-07-01
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2017-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00541229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00541229, "Sitagliptin Dose Comparison Study in Patients With Type 2 Diabetes (MK-0431-077)(COMPLETED)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00541229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*